Direct Oral Anticoagulants

DRUG4 trials

Sponsors

University of Malta, University of Birmingham, University Hospital, Brest

Conditions

Atrial FibrillationCerebral Vein ThrombosisEssential ThrombocythemiaHigh-risk PatientsJAK2 V617FOvarian Vein ThrombosisPolycythemia VeraPrefibrotic/Early Primary Myelofibrosis

Phase 3

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

University of BirminghamSubsegmental Pulmonary Embolism Nos

Start: 2021-04-08End: 2024-05-31Target: 1466Updated: 2021-09-29

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

RecruitingNCT05198960

University Hospital, BrestEssential Thrombocythemia, High-risk Patients, JAK2 V617F +2

Start: 2022-07-13End: 2027-07-13Target: 1308Updated: 2026-03-20

Phase 4

Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation

RecruitingNCT04700826

University of BirminghamAtrial Fibrillation

Start: 2021-06-01End: 2031-01-31Target: 3000Updated: 2025-05-16

Unknown Phase

DOAC in Unusual Site Venous Thrombosis

CompletedNCT03778502

University of MaltaCerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis +2

Start: 2019-10-01End: 2024-12-31Updated: 2025-07-03